Claims for Patent: 4,005,209

Summary for Patent: 4,005,209

Title:	Antiarrhythmic method utilizing fluoroalkoxy-N-piperidyl and pyridyl benzamides
Abstract:	Certain compounds in which a carbon atom of a pyrrolidine or piperidine ring is bonded directly or through a methylene group to the nitrogen of a substituted benzamido group, and their pharmaceutically acceptable salts, are found to be active as antiarrhythmic agents.
Inventor(s):	Banitt; Elden H. (Woodbury, MN), Bronn; William R. (St. Paul, MN)
Assignee:	Riker Laboratories, Inc. (Northridge, CA)
Application Number:	05/580,891
Patent Claims:	1. A method for the treating and prevention of arrhythmias in a mammal in need thereof comprising administering an effective dose less than the toxic amount of the compound of the formula: ##STR34## wherein R.sub.f is a perfluoroalkyl radical containing from one to three carbon atoms, n is one to three, p is one or two, Q is a carbon-nitrogen bond, methylene or methylmethylene and R and R' are hydrogen, methyl or ethyl, or a pharmaceutically acceptable salt thereof, to said mammal. 2. The process of claim 1 wherein the route of administration is oral. 3. A method according to claim 1 wherein p is 2. 4. A method according to claim 1 wherein R.sub.f is trifluoromethyl, n is two and the substituents are in the 2,5positions. 5. A method for the treating and prevention of arrhythmias in a mammal in need thereof comprising administering an effective dose less than the toxic amount of a compound of the formula: ##STR35## wherein R.sub.f is a perfluoroalkyl radical containing from one to three carbon atoms, n is one to three, p is one or two, Q is methylene or methylmethylene and R and R'are hydrogen, methyl or ethyl, or a pharmaceutically acceptable salt thereof to said mammal. 6. A method according to claim 5 wherein R.sub.f is trifluoromethyl, n is two and the substituents are in the 2,5 positions. 7. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-[(1-methyl-2-piperidyl)methyl]benzamide or a pharmaceutically acceptable salt thereof. 8. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-(3-piperidyl)-benzamide or a pharmaceutically acceptable salt thereof. 9. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-[(1-ethyl-2-piperidyl)methyl]benzamide or a pharmaceutically acceptable salt thereof. 10. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-[(1-ethyl-2-pyrrolidyl)methyl]benzamide, or a pharmaceutically acceptable salt thereof. 11. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-]1-(2-piperidyl)-ethyl]benzamide or a pharmaceutically acceptable salt thereof. 12. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-[(6-methyl-2-piperidyl)methyl]benzamide or a pharmaceutically acceptable salt thereof. 13. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-[(6-methyl-2-piperidyl)methyl]benzamide hydrochloride. 14. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)benzamide or a pharmaceutically acceptable salt thereof. 15. The method according to claim 1 wherein the compound is 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)benzamide hydrochloride